3rd How to Diagnose and Treat Acute Leukaemias

ESH 3rd How to Diagnose and Treat:
Acute Leukaemias

NEW DATES March 10-13, 2022 – E-CONFERENCE

#ESHAL2022

Chairs: Hervé Dombret, Gert Ossenkoppele, Jorge Sierra, Wendy Stock

In view of continuing COVID-19 related challenges and uncertainties,
the ESH 3rd How to Diagnose and Treat Acute Leukaemias conference
will be held as a VIRTUAL EVENT.

The safety of our speakers and attendees comes first.
We successfully transformed our last 14 conferences into E-Conferences
and will place you in the best dispositions to enjoy the presentations and discussions.

Participants will be joining us from all over the world and from different time zones.
To make sure that everyone has access to the full scientific programme
at a convenient hour, registration will allow participants to join both
the LIVE PROGRAMME: March 10-13, 2022
and the PROGRAMME ON-DEMAND: March 1 – April 13, 2022

REGISTRATION IS OFFERED FREE OF CHARGE
as a gesture of solidarity during these difficult times.

Registration now open!

About the Conference:

ESH How to Diagnose and Treat meetings are disease-specific meetings that address state-of-the-art diagnostic and clinical management which is greatly facilitated by and discussion of real clinical cases. An important incentive will be to promote interaction between the speakers and participants.

Novel and still evolving insights into the biology and diagnosis of acute leukaemias, including acute myeloid leukaemias (AMLs) and acute lymphoblastic leukaemias (ALL), has resulted in new drug approvals and new therapeutic options to treat newly-diagnosed as well as relapsed/refractory disease.

The programme of this “3rd How to Diagnose and Treat: Acute Leukaemias” meeting will integrate of genomic analysis and cutting-edge technics in routine diagnosis, gene mutation-directed therapies and new standard treatment algorithms, allogeneic haematopoietic stem cell (HSCT) transplantation and innovative immunotherapies, as well as diagnosis and management of rare acute leukaemia subtypes.

This meeting will be valuable for you if you are looking for:
• A high-quality scientific programme – from basic science to clinical and therapeutic applications together a glimpse in the future
• Many opportunities for scientific interaction with an international faculty of distinguished leukemia experts
• Ample time for critical discussion
• The meeting will provide state-of-the-art recommendations regarding patient care and insights into controversies and new therapeutic perspectives in the field.

This meeting will be of interest to:
• Senior biologists and clinicians, including experts in the field (MD, PhD, MD-PhD)
• Junior biologists and clinicians (MD, PhD)
• Clinical residents still in-training
• Allied health care professionals

Learning objectives:
• Get knowledge of diagnostic tests needed to optimally manage patients with AML and ALL
• Get insight in new treatment strategies available for AML and ALL patients for front-line and for salvage therapy
• Maintenance treatment
• Understand the value of measurable residual disease (MRD) levels to direct acute leukaemia therapy
• Gain insight into emerging mechanisms associated with clinical resistance and leukaemia escape
• Understand the effects and place of new immunotherapies with respect to standard or new HSCT procedures

Topics :
• Diagnosis and rare diseases
• Measurable Residual Disease (MRD)
• Leukaemia treatment dilemmas
• Intensive chemotherapy for older fit patients
• MRD level before transplant
• Leukaemia treatment challenges
• Ph-positive ALL
• CAR-T cell for ALL patients
• Immune therapies to treat leukaemia patients
• Haematopoietic stem cell transplantation

The programme will include:
• Plenary Sessions
• Interactive Case Presentations
• Roundtables
• Panel Discussions
• Debates
• Meet the Expert Sessions
• Poster Walks
• Voting technology

SUBMISSION OF ABSTRACTS AND CLINICAL CASES IS NOW CLOSED.

Clinical Case Presentation:

• Clinical cases must be relevant to the topic of the meeting. 
• Maximum number of words: 500 
• Your clinical case will be submitted to peer review. 

 Abstracts:

• Your abstract can be structured (eg Objectives, Methods, Results, Conclusions) or unstructured. 
• Maximum number of words: 500 
• Your abstract will be submitted to peer review.

N/A

Virtual tour of the E-Conference platform:

With the support of*:

Major E-Conference Partner

*******

Level 1 E-Conference Partners

*******

Level 2 E-Conference Partner

*******

Supporting E-Conference Partner

*******

*ESH conference programmes are developed in strict scientific independence
with no input from corporate sponsors.

The registration for the 3rd How To Diagnose and Treat Acute Leukaemias E-Conference is offered FREE OF CHARGE, as a gesture of solidarity during these difficult times.

Meet the Expert sessions: Registration fee: 20€
These sessions will be open to E-Conference academic biologists and clinicians registrants only. A maximum of 30 seats will be available in each session and pre-registration will therefore be required.